Biotech stocks haven’t seen much of a momentum thus far in the new year amid a lack of meaningful catalysts. The bygone week saw two FDA approvals: Horizon Therapeutics PLC’s (NASDAQ: HZNP ) thyroid eye … …read more
Source:: Yahoo Finance
Biotech stocks haven’t seen much of a momentum thus far in the new year amid a lack of meaningful catalysts. The bygone week saw two FDA approvals: Horizon Therapeutics PLC’s (NASDAQ: HZNP ) thyroid eye … …read more
Source:: Yahoo Finance
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.